Larotrectinib (NTRK inhibitor) and selpercatinib (RET inhibitor) have shown dramatic efficacy in clinical trials in both solid tumors and hematologic malignancies, including a limited number of thyroid tumors harboring NTRK and RET fusions included in these studies. Here, RET is linked to hematologic disorder.